WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H593204
CAS#: 2088453-79-4
Description: OAT-1441 is a hAMCase inhibitor.
Hodoodo Cat#: H593204
Name: OAT-1441
CAS#: 2088453-79-4
Chemical Formula: C23H27ClN6O
Exact Mass: 438.19
Molecular Weight: 438.960
Elemental Analysis: C, 62.93; H, 6.20; Cl, 8.08; N, 19.15; O, 3.64
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: OAT-1441; OAT-1441; OAT1441
IUPAC/Chemical Name: (S)-3-(4-(3-(4-chlorobenzyl)-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)piperidin-1-yl)-1H-1,2,4-triazol-5-amine
InChi Key: TYNJYIOCKJBQLY-FQEVSTJZSA-N
InChi Code: InChI=1S/C23H27ClN6O/c24-18-7-5-16(6-8-18)13-20-15-31-21-4-2-1-3-17(21)14-30(20)19-9-11-29(12-10-19)23-26-22(25)27-28-23/h1-8,19-20H,9-15H2,(H3,25,26,27,28)/t20-/m0/s1
SMILES Code: NC1=NC(N2CCC(N3CC(C=CC=C4)=C4OC[C@@H]3CC5=CC=C(Cl)C=C5)CC2)=NN1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 438.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Gleb Andryianau, Michal Kowalski, Michal C. Piotrowicz, Adam A. Rajkiewicz, Barbara Dymek, Piotr L. Sklepkiewicz, Elzbieta Pluta, Filip Stefaniak, Wojciech Czestkowski, Sylwia Olejniczak, Marzena Mazur, Piotr Niedziejko, Robert Koralewski, Krzysztof Matyszewski, Mariusz Gruza, Agnieszka Zagozdzon, Magdalena Salamon, Aleksandra Rymaszewska, Mikolaj Welzer, Karolina Dzwonek, Jakub Golab, Jacek Olczak, Agnieszka Bartoszewicz, and Adam Golebiowski. Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase.J Med Chem. 2018 April 24. DOI: 10.1021/acsmedchemlett.0c00092